Skip to main content
Immunovia logo

Immunovia — Investor Relations & Filings

Ticker · IMMNOV ISIN · SE0006091997 LEI · 549300KHWL6KK1XGUO81 ST Human health and social work activities
Open in API
Filings indexed 374 across all filing types
Latest filing 2024-08-06 Capital/Financing Update
Country SE Sweden
Listing ST IMMNOV

About Immunovia

https://immunovia.com/

Immunovia is a diagnostics company focused on revolutionizing the early detection of pancreatic cancer. Its primary product is the PancreaSure test, a simple blood test designed to detect pancreatic cancer at Stage 1 and 2 with high accuracy. The test is intended for annual surveillance of individuals at elevated risk due to family history or genetic mutations. PancreaSure functions by detecting proteins and other biomarkers indicative of pancreatic cancer growth. The company's mission is to improve survival rates for this highly lethal cancer by enabling diagnosis at its earliest, most treatable stages, offering a convenient alternative to invasive imaging procedures.

Recent filings

Filing Released Lang Actions
Immunovia announces final terms of rights issue
Capital/Financing Update Classification · 1% confidence The document is a press release dated August 6, 2024, announcing the 'final terms of rights issue' for Immunovia AB. It details the structure of the rights issue (units, shares, warrants), subscription price, expected proceeds, subscription period (August 16 - August 30, 2024), and the impact on share capital and dilution. This content directly relates to a company fundraising or capital structure change event. This aligns perfectly with the definition of 'Capital/Financing Update' (CAP). Although it mentions the Annual General Meeting approved the issue, the core subject is the financing terms, not AGM materials or voting results.
2024-08-06 English
Interim / Quarterly Report 2024
Interim / Quarterly Report Classification · 1% confidence The document is titled 'DELÅRSRAPPORT JANUARI-JUNI 2024' (Interim Report January-June 2024). It contains comprehensive financial statements, including income statements, balance sheets, cash flow statements, and management commentary for the interim period. It is not a short announcement, but a full report, thus fitting the definition of an Interim/Quarterly Report (IR). H1 2024
2024-08-05 Swedish
Interim / Quarterly Report 2024
Interim / Quarterly Report Classification · 1% confidence The document is titled 'INTERIM REPORT JANUARY-JUNE 2024' and contains comprehensive financial statements, including income statements, cash flow statements, and balance sheets for the specified period. It provides detailed management commentary, key performance indicators, and accounting principles. It is not a short announcement or a certification, but the full interim financial report itself, fitting the definition of an Interim/Quarterly Report (IR). H1 2024
2024-08-05 English
Major Shareholding Notification 2024
Major Shareholding Notification Classification · 1% confidence The document explicitly details a change in shareholding ('Holder' is Avanza Bank Holding AB for Avanza Pension) due to a 'Sell' transaction, resulting in a new percentage of ownership (7.2313%). It mentions 'Flaggning sker för passerat tröskelvärde beträffande det aggregerade innehavet' (Flagging occurs for passing the threshold regarding the aggregate holding). This structure—reporting changes in significant share ownership that cross predefined thresholds—directly corresponds to the definition of a Major Shareholding Notification. The code for this is MRQ.
2024-08-02 English
BULLETIN FROM THE ANNUAL GENERAL MEETING ON 19 JUNE 2024 IN IMMUNOVIA AB (PUBL)
AGM Information Classification · 1% confidence The document is explicitly titled 'BULLETIN FROM THE ANNUAL GENERAL MEETING ON 19 JUNE 2024 IN IMMUNOVIA AB (PUBL)' and details the resolutions adopted during that meeting, such as the adoption of accounts, discharge from liability, election of the board, approval of remuneration reports, and resolutions regarding share capital reduction and rights issues. These are the core components of an Annual General Meeting (AGM) proceeding summary. Therefore, the appropriate classification is AGM-R (AGM Information).
2024-06-19 English
KOMMUNIKÉ FRÅN ÅRSSTÄMMA DEN 19 JUNI 2024 I IMMUNOVIA AB (PUBL)
AGM Information Classification · 1% confidence The document is explicitly titled "KOMMUNIKÉ FRÅN ÅRSSTÄMMA DEN 19 JUNI 2024 I IMMUNOVIA AB (PUBL)" (Communication from the Annual General Meeting held on June 19, 2024). It details the resolutions passed at the meeting, including approval of accounts, election of the board, remuneration, capital reduction, changes to the articles of association, and approval of a rights issue. These are the core components of an Annual General Meeting (AGM) outcome announcement. Therefore, the correct classification is AGM-R (AGM Information). The document is not a full Annual Report (10-K) or a proxy statement (PSI), but a summary of the meeting's decisions.
2024-06-19 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.